Extended Data Fig. 5: Adverse Events Leading to Treatment Discontinuation (AdvSM Safety Population, N = 69).
From: Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
*Events determined to be probably or possibly related to the study medication. †Acute myeloid leukemia is a progressive disease event that was also reported as an AE in these 3 cases. ‡Cognitive disorder and encephalopathy occurred in the same patient. §Staphylococcal sepsis and thrombocytopenia occurred in the same patient. AdvSM, advanced systemic mastocytosis.
